Does Early Pancreatic Recovery Change The Bull Case For Vertex Pharmaceuticals (VRTX)?

Simply Wall St.10-15

Vertex Pharmaceuticals reported interim data from an open label extension study of ALYFTREK in 2 to 5 year old children with cystic fibrosis, showing recovery of exocrine pancreatic function in some ...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2675309309?lang=en_US&edition=fundamental","thumbnail":"https://simplywall.st/cdn-cgi/image/fit=cover,format=auto,width=320,height=180/https://images.simplywall.st/asset/company-cover/36235-card/1788967613256","is_english":true,"pubTime":"2026-10-15 14:25","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2675309309","market":"us","top_or_hot":-1,"title":"Does Early Pancreatic Recovery Change The Bull Case For Vertex Pharmaceuticals (VRTX)?","media":"Simply Wall St.","content":"<div>\n<p>Vertex Pharmaceuticals reported interim data from an open label extension study of ALYFTREK in 2 to 5 year old children with cystic fibrosis, showing recovery of exocrine pancreatic function in some ...</p>\n\n<a href=\"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-vrtx/vertex-pharmaceuticals/news/does-early-pancreatic-recovery-change-the-bull-case-for-vert\">Source Link</a>\n\n</div>\n","source":"simplywall_highlight","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Does Early Pancreatic Recovery Change The Bull Case For Vertex Pharmaceuticals (VRTX)?</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nDoes Early Pancreatic Recovery Change The Bull Case For Vertex Pharmaceuticals (VRTX)?\n</h2>\n\n<h4 class=\"meta\">\n\n\n2026-10-15 14:25 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-vrtx/vertex-pharmaceuticals/news/does-early-pancreatic-recovery-change-the-bull-case-for-vert><strong>Simply Wall St.</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Vertex Pharmaceuticals reported interim data from an open label extension study of ALYFTREK in 2 to 5 year old children with cystic fibrosis, showing recovery of exocrine pancreatic function in some ...</p>\n\n<a href=\"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-vrtx/vertex-pharmaceuticals/news/does-early-pancreatic-recovery-change-the-bull-case-for-vert\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"LU1585245621.USD","symbol_name":"EASTSPRING INV GLOBAL LOW VOLATILITY EQUITY FUND \"A\" (USD) ACC B","start_time":0,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-vrtx/vertex-pharmaceuticals/news/does-early-pancreatic-recovery-change-the-bull-case-for-vert","article_id":"2675309309","we_media_id":null,"thumbnails":["https://simplywall.st/cdn-cgi/image/fit=cover,format=auto,width=320,height=180/https://images.simplywall.st/asset/company-cover/36235-card/1788967613256"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-vrtx/vertex-pharmaceuticals/news/does-early-pancreatic-recovery-change-the-bull-case-for-vert","rn_cache_url":null,"directOrigin":true},"url":"https://stock-news.laohu8.com/highlight/detail?id=2675309309","pubTimestamp":1792045529,"columns":[],"sourceInfo":{"source_id":"simplywall_highlight","name":"Simply Wall St."},"weMediaInfo":null,"summary":"Vertex Pharmaceuticals reported interim data from an open label extension study of ALYFTREK in 2 to 5 year old children with cystic fibrosis, showing recovery of exocrine pancreatic function in some participants and enabling discontinuation of pancreatic enzyme replacement therapy for a subset.\nThe finding that pancreatic exocrine insufficiency in young children with cystic fibrosis may be reversible challenges long held clinical assumptions and underscores how earlier CFTR modulator use...","collect":0,"end_time":0,"defaultTopTitle":"simplywall.st","property":[],"viewcount":null,"language":"en","relate_stocks":{"LU1585245621.USD":"EASTSPRING INV GLOBAL LOW VOLATILITY EQUITY FUND \"A\" (USD) ACC B","LU1035775433.USD":"AB SICAV I - AMERICAN GROWTH PORTFOLIO \"AD\" (USD) INC","SG9999001176.USD":"United Global Healthcare Acc USD","IE00BZ9MQY76.HKD":"FTGF CLEARBRIDGE US AGGRESSIVE GROWTH \"A\" (HKD) ACC","IE00B2B36J28.USD":"JANUS HENDERSON GLOBAL LIFE SCIENCES \"I1\" (USD) INC","LU1093756168.USD":"FRANKLIN K2 ALTERNATIVE STRATEGIES \"A\" (USD) ACC","LU1674673691.USD":"HSBC GIF GLOBAL LOWER CARBON EQUITY \"AD\" (USD) INC","LU1069344957.HKD":"AB SICAV I - AMERICAN GROWTH PORTFOLIO \"AD\" (HKD) INC","IBB":"生物科技指数ETF-iShares Nasdaq","LU0432979614.USD":"JPM GLOBAL HEALTHCARE \"A\" ACC","LU2362540622.SGD":"WELLINGTON NEXT GENERATION GLOBAL EQUITY \"A\" (SGDHDG) ACC","IDNA":"iShares Genomics Immunology and Healthcare ETF","LU0234570918.USD":"高盛全球核心股票组合Acc Close","LU1674673428.USD":"HSBC GIF GLOBAL LOWER CARBON EQUITY \"AC\" (USD) ACC","TBXU":"Direxion Daily Biotech Top 5 Bull 2X ETF","BIB":"Ultra纳斯达克生物科","LU0417517546.SGD":"Allianz US Equity Cl AT Acc SGD","BK4023":"应用软件","IBBQ":"Invesco Nasdaq Biotechnology ETF","IE00BJJMRZ35.SGD":"JANUS HENDERSON GLOBAL LIFE SCIENCES \"I2\" (SGDHDG) ACC","LU0079474960.USD":"联博美国增长基金A","LU0256863811.USD":"ALLIANZ US EQUITY \"A\" INC","LU0757428866.USD":"THREADNEEDLE (LUX) GLOBAL SMALLER COMPANIES \"AE\" (USD) ACC","LU2462157665.USD":"ALLIANZ GLOBAL INCOME \"A\" (USD) INC","LU0320765992.SGD":"FTIF - Franklin Biotechnology Discovery A Acc SGD","IE00B19Z3B42.SGD":"Legg Mason ClearBridge - Value A Acc SGD","BK4585":"ETF&股票定投概念","BK4567":"ESG概念","GNMX":"Corgi Genomics & Precision Medicine ETF","PBE":"INVESCO BIOTECHNOLOGY & GENOME ETF","LU1815336091.USD":"THREADNEEDLE (LUX) GLOBAL SMALLER COMPANIES \"AUP\" (USD) INC","BK4139":"生物科技","BK4533":"AQR资本管理(全球第二大对冲基金)","SG9999013999.USD":"UOB UNITED GLOBAL HEALTHCARE FUND (USDHDG) INC","LU0109394709.USD":"富兰克林生物科技新领域基金A (acc)","LU0823416689.USD":"BNP PARIBAS HEALTH CARE INNOVATORS \"C\" (USD) ACC","LU2417539215.USD":"ALLIANZ GLOBAL INCOME \"AMF\" (USD) INC","SG9999001176.SGD":"UOB UNITED GLOBAL HEALTHCARE \"SGD\" (ACC)","IE00B19Z9P08.USD":"LEGG MASON CLEARBRIDGE US AGGRESSIVE GROWTH \"A\" (USD) INC","VRTX":"福泰制药","IE00B894F039.SGD":"Legg Mason ClearBridge - US Aggressive Growth A Acc SGD-H","LU1778281490.HKD":"HSBC GIF GLOBAL LOWER CARBON EQUITY \"AD\" (HKD) INC","LU0058720904.USD":"联博国际健康护理基金A","LU2237438978.USD":"Amundi Funds US Pioneer A2 (C) USD","LU2324357040.USD":"HSBC GIF GLOBAL EQUITY SUSTAINABLE HEALTHCARE \"AC\" (USD) ACC","BBH":"VanEck Biotech ETF","LU2468319806.SGD":"MANULIFE GF HEALTHCARE \"AA\" (SGDHDG) ACC","LU1559883803.SGD":"Aberdeen Standard SICAV I - North American Smaller Companies Fund A Acc SGD-H","VERX":"Vertex, Inc.","LU2362541273.HKD":"WELLINGTON NEXT GENERATION GLOBAL EQUITY \"A\" (HKD) ACC"},"translate_title":"早期胰腺恢复是否会改变 Vertex Pharmaceuticals (VRTX) 的牛市？","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"GNMX":0.6,"IDNA":0.6,"IBBQ":0.6,"VRTX":1.5,"TBXU":0.6,"IBB":0.6,"PBE":0.6,"BIB":0.6,"BBH":0.6,"VERX":1.5},"content_text":"Vertex Pharmaceuticals reported interim data from an open label extension study of ALYFTREK in 2 to 5 year old children with cystic fibrosis, showing recovery of exocrine pancreatic function in some participants and enabling discontinuation of pancreatic enzyme replacement therapy for a subset. The finding that pancreatic exocrine insufficiency in young children with cystic fibrosis may be reversible challenges long held clinical assumptions and underscores how earlier CFTR modulator use could reshape Vertex Pharmaceuticals’ long term treatment burden and care model in its core franchise. The focus now turns to how Vertex Pharmaceuticals’ investment narrative could be influenced by early pancreatic function recovery seen with ALYFTREK.  Scan 34 healthcare AI stocks, which, like Vertex Pharmaceuticals, are working at the intersection of cutting-edge therapies and data-driven medicine in areas where standard care has barely begun to shift. AdvertisementVertex Pharmaceuticals Investment Narrative Recap To own Vertex Pharmaceuticals, you need to believe its cystic fibrosis engine can remain resilient while newer pillars like gene editing, renal disease and endocrinology mature. The ALYFTREK pancreatic data points to deeper clinical impact in CF, but does not change that the key near term swing factor is how fast new launches such as CASGEVY and JOURNAVX build into the revenue mix. The biggest current risk still sits with CF concentration and global pricing pressure, especially as management is already signaling slower company wide revenue growth compared with prior years and some peers. The ALYFTREK update helps the franchise story, yet it does little to alter exposure to reimbursement decisions or to execution on integrating the Crinetics deal. The ALYFTREK data in 2 to 5 year olds lines up directly with one of the main catalysts analysts focus on. Management has been pushing rapid uptake and broader access for new CFTR modulators, and proof that some children can come off lifelong pancreatic enzyme replacement therapy strengthens the clinical rationale for earlier use in eligible patients. For investors tracking catalysts, the key question is how this type of result supports Vertex Pharmaceuticals as it leans on five commercial pillars and raised 2026 revenue guidance to US$13.1b to US$13.2b. Stronger real world validation in CF can help underpin high margin cash flows that fund renal, endocrinology and gene editing programs, while still leaving the business exposed to volume or pricing headwinds in its largest franchise. Vertex Pharmaceuticals' current analyst narrative points to revenues of US$17.6b and earnings of US$6.3b by 2029, based on an assumed 11.7% yearly revenue growth rate and a forecast move in earnings from US$4.4b today to US$6.3b, which represents an increase of about US$1.9b in forecast consensus earnings. Uncover why Vertex Pharmaceuticals' fair value indicates a 15% potential upside to its current price that may not last much longer. NasdaqGS:VRTX 1-Year Stock Price Chart Exploring Other Perspectives You see the biggest contrast around margin pressure. The most bearish analysts already penciled in revenue of about US$16.3b and earnings of US$5.1b by 2029, with margins tightening as support programs and higher costs bite. That is a far gloomier Vertex Pharmaceuticals storyline, and the fresh ALYFTREK data could eventually shift those expectations.\nExplore 5 other Vertex Pharmaceuticals fair value estimates, including one that suggests as much as 13% downside from the current price. Form Your Own Verdict Don't just follow the ticker; dig into the data and build a conviction that's truly your own.  A great starting point for your Vertex Pharmaceuticals research is our analysis highlighting 3 key rewards that could impact your investment decision. See our latest analysis for Vertex Pharmaceuticals. The report includes a comprehensive fundamental analysis summarized in a single visual, the Snowflake, making it easy to evaluate Vertex Pharmaceuticals' overall financial health at a glance.  Looking For More Ideas Beyond Vertex Pharmaceuticals? Once you have a view on Vertex Pharmaceuticals, it can help to widen the lens and compare it with other companies that fit different risk and reward profiles using the Simply Wall St Screener.  For investors who want potential mispricing with quality fundamentals, scan a curated 32 high quality undervalued stocks that might offer a different balance of price and business strength. If capital preservation comes first, focus on resilience by reviewing a 32 resilient stocks with low risk scores that may help reduce portfolio volatility. When you want sturdier balance sheets backing your thesis, filter for companies using the list of solid balance sheet and fundamentals (25 results) to see which businesses pair financial strength with fundamental support.   This article by Simply Wall St is general in nature. We provide commentary based on historical data\n        and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your\n        financial situation. We aim to bring you long-term focused analysis driven by fundamental data.\n        Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material.\n        Simply Wall St has no position in any stocks mentioned.New: Manage All Your Stock Portfolios in One PlaceWe've created the ultimate portfolio companion for stock investors, and it's free.• Connect an unlimited number of Portfolios and see your total in one currency• Be alerted to new Warning Signs or Risks via email or mobile• Track the Fair Value of your stocksTry a Demo Portfolio for FreeHave feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":false,"editions":null,"column":"","sentiment":"1","news_tag":"","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.52.0","shortVersion":"4.52.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2675309309","isCrawlerRequest":true}